SUMMARY A simulated randomized clinical trial in coronary artery disease was conducted to illustrate the need for clinical judgment and modern statistical methods in assessing therapeutic claims in studies of complex diseases. Clinicians should be aware of problems that occur when a patient sample is subdivided and treatment effects are assessed within multiple prognostic categories. In this example, 1073 consecutive, medically treated coronary artery disease patients from the Duke University data bank were randomized into two groups. The groups were reasonably comparable and, as expected, there was no overall difference in survival. In a subgroup of 397 patients characterized by three-vessel disease and an abnormal left ventricular contraction, however, survival of group 1 patients was significantly different from that of group 2 patients. Multivariable adjustment procedures revealed that the difference resulted from the combined effect of small imbalances in the distribution of several prognostic factors. Another subgroup was identified in which a significant survival difference was not explained by multivariable methods.
These are not unlikely examples in trials of a complex disease. Clinicians must exercise careful judgment in attributing such results to an efficacious therapy, as they may be due to chance or to inadequate baseline comparability of the groups.
CLINICAL JUDGMENT in chronic illness involves a knowledge of the natural history of the disease, the ability to assess the validity of therapeutic claims and a means of applying what is known to the individual patient. Much has been written about the natural history of angina pectoris.1-10 The literature has emphasized the importance of multiple factors in determining outcome and of the heterogeneity of patients grouped together under the diagnosis of angina pectoris. This complexity makes the clinician's task of interpreting therapeutic claims particularly difficult. In this paper, a simulated randomized clinical trial in patients with coronary artery disease is presented to illustrate the effects that the heterogeneity of patients with angina pectoris may have on the results of clinical experiments. The role of statistics and clinical judgment in solving the problems encountered is explored. The randomized design is used because it represents the ideal method of treatment allocation in clinical experiments. The problems and the approaches to their solutions apply equally well to both randomized and nonrandomized clinical studies.
Methods
The subjects in this simulated trial consisted of the medically treated patients with angiographically proved coronary artery disease contained in the Duke University data bank. The data bank has been described previously." Briefly, baseline historical, physical examination, laboratory, electrocardiographic, stress test, chest x-ray, angiographic data and follow-up information on 1073 medically treated patients with significant coronary artery disease formed the basis of this study. Significant disease was defined as at least a 75% occlusion of one or more coronary arteries. This population represents all consecutive patients with coronary artery disease who were catheterized and treated medically at Duke University Medical Center between August 1969 and January 1977. The baseline characteristics were carefully collected and entered into the data bank during each patient's initial hospital evaluation.
These patients and their baseline and follow-up data were used to simulate a randomized clinical trial. The patients were randomized into two groups, designated "treatment" group 1 and "treatment" group 2. In this experiment, the patients received the same treatment, but the two groups would correspond to different therapeutic interventions in an actual clinical trial. The experimental design was similar to that used in the VA Cooperative Study of coronary artery bypass surgery.12 The 1073 patients were stratified (blocked) according to age (under 50 years and 50 years and older) and the number of significantly diseased vessels (one, two or three). Randomization to group 1 or group 2 was performed separately within each of the six prognostic strata. In an actual trial, randomization would be performed at the time of patient entry into the study. This was mimicked in the simulated trial by allocating patients according to the date of cardiac catheterization. Well-described balancing methods were used to ensure relative chronologic balance between "treatments."'3 Random numbers were generated using an automated shift-register, randomnumber generator.14 Group 1 and group 2 were compared with respect to the distribution of baseline characteristics in order to determine whether equalization of baseline abnormalities had been achieved. prognostically important baseline characteristics on survival were examined in the subgroups using the same methods detailed above.
Results Selected baseline characteristics of the patients in this experiment are presented in table 1. Univariate statistical comparisons of the variables yielded no significant differences between groups 1 and 2 except in left ventricular contraction pattern.
As expected, yearly life-table survival rates of the randomized groups 1 and 2 were similar: 89.7% and 89.2% at 1 year, 76.9% and 79.1% at 3 years and 69.3% and 72.0% at 5 years. All multivariable methods indicated that the overall survival of group 1 and group 2 patients was consistent with the distribution of baseline characteristics and was not affected by the "treatment" (i.e., randomization). Survival rates for each of the strata (defined by number of diseased vessels and age) within which the patients were randomized are given in table 2.
The prognostic significance of the baseline variables in table 1 was assessed by the Cox model,17 and the patient population was stratified with respect to two prognostically important descriptors: the number of diseased coronary vessels (one, two or three) and left ventricular contraction pattern (normal or abnormal). In one of the resulting six subgroups, a statistically Additional stratification based on a third prognostic variable, history of congestive heart failure (yes or no), was also done. In the subgroup consisting of 143 group 1 and 155 group 2 patients with three-vessel disease, an abnormal left ventricular contraction pattern and no history of congestive heart failure, the significance of the two-group "treatment" comparison was even more dramatic (x2 = 10.0;p < 0.01). Threeyear survival rates were 60% and 80% in groups 1 and 2, respectively.* Again, the prevalence of other prognostically important baseline abnormalities in this subgroup appeared slightly higher in group 1 than in group 2 patients. In this case, however, the significance of the observed difference in survival between the two groups persisted after adjusting for multiple prognostic characteristics. (After adjusting for the variables in table 3, the chi-square for "treatment" was 9.3, p < 0.01.) Discussion This simulated randomized clinical trial was performed to illustrate problems that may arise in assess-*The Cox and Mantel-Haenszel statistics take into account the overall structure of the survival curves being compared, not just their values at one time point. The pattern of deaths in this particular subset explains the more significant "treatment" comparison. Twice as many deaths (22 vs 1 1) occurred during the first year in group 1 compared with group 2; this dramatic early difference was maintained throughout the follow-up period. By contrast, in the 397 patients in the larger subgroup, the pattern of deaths did not cause a marked separation in the survival curves until the third year (see fig. 1 ). Abbreviations: CHF = congestive heart failure; AVO2D = arteriovenous oxygen difference; LV = left ventricular.
ing therapeutic effects when seeking information relevant to specific patients from a study that contains patients with various prognoses. The problems of subgrouping patients according to prognostic descriptors and performing treatment comparisons within some or all of the subgroups are well known to biostatisticians, and to many clinicians on a theoretical basis, but have not received adequate practical attention in real clinical trials.
Many randomized trials in chronic disease are prospectively designed to answer a single, usually rather broad question. At completion, such trials are frequently best known for the answers to questions that were asked retrospectively in particular patient subgroups. For example, in the University Group Diabetes Program, a prospective study was undertaken to determine whether various treatments would affect the development of vascular complications in a selected group of diabetic patients.20 The controversial claim from this study that in certain patients tolbutamide increased the risk of cardiovascular deaths21, 22 iS well known. The Veterans Administration Cooperative Study of Surgery for Coronary 24 From the results of this simulated trial, one might attempt to explain the differences in outcome between patients from groups 1 and 2 in the second subgroup by postulating differences in other baseline characteristics. Indeed, one may legitimately ask whether a more quantitative measure of ventricular function (e.g., ejection fraction) or information about the actual medical treatment received may have explained the difference in survival. Recognizing that random patient allocation does not guarantee equal distribution of all risk factors, particularly in subgroups selected for examination after the study was designed and data were collected, there are undoubtedly factors that might explain many such differences in outcome. Despite sophisticated statistical techniques, however, when many subgroups are analyzed, there will be differences in outcome that cannot be explained by baseline differences of known variables. In such cases there are four possible explanations: 1) the patients were inadequately characterized; 2) the patients were adequately characterized but the statistical methods were inadequate to properly relate baseline differences to outcome; 3) the treatment was effective; or 4) the difference was due to chance.
In assessing therapeutic claims, the doctor must consider the adequacy of the experimental design and conduct of the study, the adequacy of the analysis and presentation of results, the strength of the conclusion and how the findings relate to his clinical experience and to clinical knowledge. The essential components of experimental design have been reviewed.27 We and others have discussed modern multivariable analysis techniques.23 24 Regarding strength of the conclusion, one will normally have more confidence in results significant at the 0.0001 level than in those that achieve only the 0.05 level. The consistency of therapeutic effects over time (e.g., as observed by subdividing the follow-up period and analyzing the data within more than one time interval) will also strengthen the conclusion.24
If satisfied with the adequacy of the design and analysis, the clinician must weigh results of a clinical trial with what his training and experience could reasonably lead him to expect. For example, the clinician might expect that treatment would affect more than one manifestation of the target disease. In coronary artery disease, a therapy that reduces the frequency of anginal pain and death might be expected to reduce the frequency of nonfatal myocardial infarction as well. A therapy that increases survival in left main coronary artery disease might also be expected to improve survival, though perhaps less dramatically, *If k is the number of subgroups to be examined, requiring the p value of each comparison to be less than a/k will assure an overall level of significance for the k tests that is no greater than a, regardless of whether the tests are independent. 512 CIRCULATION in three-vessel disease. Such expectations are based on clinical experience and biologic principles. Finally, results of different studies that are designed and analyzed adequately should be consistent. Frequently, new interpretations, especially if based on the analysis of subgroups, should be treated as tentative until confirmed by other studies.
The problems faced by the clinician in assessing therapeutic claims is well illustrated by studies of the efficacy of aortocoronary bypass surgery. Many studies use medical controls whose comparability to the surgical series has not been or cannot be determined.28-30 Because differences in survival can arise so easily in a simulated randomized trial, one should not readily accept the results of a study with unmatched controls whose baseline data are insufficient for adequate statistical analysis. In the interpretation of three studies that do have fairly reasonable controls, careful assessment is still necessary. The VA Cooperative Study is a randomized trial.31 The Duke7 and the Seattle32 groups have studied concurrent operated and nonoperated series that were not randomized. These three studies have reached some consistent conclusions. Their reports indicate that aortocoronary bypass surgery did not prolong 4-5-year survival when medically and surgically treated patients were compared overall. All reported a subgroup in which surgery did appear to improve survival. Each subgroup contained relatively high-risk patients: left main coronary artery disease,33 three-vessel disease with abnormal ventricular contraction but normal arteriovenous oxygen difference (subgroup F),7 and two-vessel disease with moderately reduced ejection fraction.32 None of the studies confirmed the differences found in others' subgroups. All claimed significance with only moderately low p values (0.02, 0.028 and 0.03). Multivariable methods were not applied to these subgroups to adjust for possible baseline differences.
In the study at Duke, continued observations of outcome in the patients with three-vessel disease, abnormal ventricular contraction and normal arteriovenous oxygen differences failed to confirm the original find is not a straightforward judgment. As our simulated study makes clear, caution is necessary, even in randomized clinical trials. In today's studies of therapeutic effects in a complex chronic disease, investigators generally accept the importance of complete, carefully collected baseline data, a comparable control group, and physiologic rationale for treatment effects. Other points such as the likelihood of chance differences achieving statistical significance when multiple subgroups are analyzed and reanalyzed, or the influence on outcome comparisons of the combined effect of several relatively small differences in baseline prognostic variables may not be so obvious. These points are often ignored or not mentioned in the presentation of results of clinical research. Clinical studies must continue to add to our understanding of diseases such as coronary artery disease and to provide information relative to the care of individual patients. We hope that the information presented here will enable clinicians to make a more careful and informed evaluation and interpretation of these studies.
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Appendix
The Cox model,17 an analog of the multiple linear regression model, was developed for the analysis of survival data. Unlike methods that consider survival at isolated time points, the Cox model takes into account the overall structure of the survival curves under study. It can accommodate varying lengths of patient followup, and it uses information on the time to death (i.e., the order in which the deaths occur) rather than simply enumerating the number of deaths. With this model, relationships can be studied between an outcome (response) variable and multiple patient baseline characteristics. The outcome variable of primary interest in most clinical follow-up studies is patient survival time; however, the time to end points other than death, such as the first myocardial infarction, can also be studied. The baseline patient descriptors may be either continuous or discrete measurements. Each baseline descriptor can be considered individually to determine whether it has a significant univariate relationship with survival. More important, however, multiple baseline characteristics can be analyzed jointly to determine which descriptors contribute independent prognostic information after adjustment for the effects of other variables. In an analysis to determine whether therapy is significantly related to survival, a treatment variable is included as one of the baseline characteristics. Therapeutic effects can thus be assessed without adjustment and with adjustment for the effects of other prognostic variables. The latter is of critical importance when there are multiple prognostic factors, some of which may be unequally distributed between treatment groups. Another advantage of the Cox model is that, in contrast to standard multiple regression procedures, it can accommodate "censored" survival times. Such observations arise because at the time of analysis, many patients are still alive, and the time to their deaths is known only to be greater than the current length of their follow-up. These patients are said to have a "censored" survival time.
A mathematical expression for the model is given by the equation loge ( A (t) )= 4 where d is the residual lumen diameter at the stenosis, U is linear flow velocity and f0 is the characteristic break frequency of the bruit, the frequency beyond which amplitude falls off with increasing frequency. 3 The algorithm, although applied with significant accuracy to evaluate the degree of carotid artery stenosis in humans, has not been tested under controlled conditions in experimental animals.
